ASCO® 2024 Insights: "LITESPARK-013 Study Subgroup Analysis - Belzutifan in Advanced ccRCC"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "LITESPARK-013 Study Subgroup Analysis - Belzutifan in Advanced ccRCC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Michael Atkins

0 views

June 10, 2024

Chapters

Belzutifan & Advanced Renal Cell Carcinoma

00:00

LITESPARK-013 Study Design & Demographics

01:56

Subgroup Efficacy Analysis Results

04:03

Conclusions & Future Research Directions

08:47

Comments 0

2024 ASCO® Annual Meeting Insights Hub: GU Videos

21:54

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Prostate Cancer Take-Home Messages

Feat. E. Efstathiou

10:19

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implicat…

Feat. K. Mittal

15:28

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Bladder and RCC Highlights"

Feat. K. Tawagi, N. Reizine

View All

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Mes…

Feat. E. Efstathiou